Integrative Proteomic Analysis Reveals Metabolic Vulnerabilities and Diagnostic Biomarkers in High-risk Prostate Cancer

Raw dataset. 1: The genomic characterization of the 125 PCa patients.
Raw dataset. 1a: Somatic mutations identified in the 125 PCa patients called by WES.
Raw dataset. 1b: Somatic copy number alterations (CNAs) identified in the 125 PCa patients called by WES (Gene level copy number alterations estimated by GISTIC2).
Raw dataset. 1c: Somatic copy number alterations (CNAs) identified in the 125 PCa patients called by WES (Arm level copy number alterations estimated by GISTIC2).
Raw dataset. 1d: Somatic copy number alterations (CNAs) identified in the 125 PCa patients called by WES (Focal copy number alterations estimated by GISTIC2).
Raw dataset. 1e: The gene fusion events identified in the 125 PCa patients called by RNA-seq data.
Raw dataset. 1f: Qualitative and quantitative results of both annotated and novel splice junctions changed in tumor and NAT of the 125 PCa patients (rMATS uses a likelihood-ratio test to calculate the P value and uses Benjamini-Hochberg multiple comparisons for FDR).

Raw dataset. 2: The transcriptomic characterization of the 125 PCa patients.
Raw dataset. 2a: A list of the genes identified in PCa samples by RNA-Seq (shown as the normalized count).
Raw dataset. 2b: A list of the genes identified in PCa samples by RNA-Seq (shown as the FPKM).

Raw dataset. 3: The proteomic characterization of the 125 PCa patients.
Raw dataset. 3a: A list of protein groups identified in the 125 PCa patients.
Raw dataset. 3b: A list of proteins (grouped into unique gene names) and their relative intensities in tumor and nearby tissues of the 125 PCa patients.

Raw dataset. 4: The phosphoproteomic characterization of the 125 PCa patients.
Raw dataset. 4a: A list of phosphosites identified in the 125 PCa patients.
Raw dataset. 4b: A list of phosphosites (grouped into unique gene names) and their relative intensities in tumor and nearby tissues of the 125 PCa patients.